康希諾(06185.HK)逆漲一成越50天線 新冠疫苗據報已獲墨西哥訂單及或獲印尼採購
康希諾生物-B(06185.HK)研發新冠肺炎疫苗或獲印尼採用及據報已獲墨西哥採購訂單。該股繼昨天整固後,今早逆市重越50天線(186.5元),最高見195元,現造193.8元,逆彈9.9%,成交增至144萬股,涉資2.738億元。
據內媒報道指,康希諾生物與中國工程院院士陳薇團隊合作研發新冠肺炎疫苗國際III期臨床試驗於墨西哥取得進展,且墨西哥已簽訂框架協議向康希諾採購3,500萬劑新冠疫苗,此外,道瓊斯報道,印尼一位高級衛生官員透露,印尼正在採取措施批准中國新冠肺炎候選疫苗投入緊急使用。阿聯酋上月已批准一款中國新冠疫苗投入緊急使用。印尼政府表示,到今年底將向中國的科興控股生物技術、中國醫藥集團及康希諾生物採購1,800萬劑新冠疫苗,這些公司新冠疫苗仍在全球多個地點進行臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.